[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"harm-reduction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:harm-reduction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,54,88,111,127,144,175,201,227,254,287,309,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100643749","pilot-study-of-an-adapted-partner-navigation-intervention-booster-session-for-sustained-healthcare-engagement-among-people-who-inject-drugs-100643749",false,"NCT07631559","Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs","Inclusion criteria:\n\nFor index participants:\n\n* 18 years of age or older at enrollment\n* History of injecting drug use\n* Completed HCV treatment within the past 3 months\n* Report a primary injecting partner willing to participate\n* Willing and able to provide informed consent\n* English or Spanish speaking\n\nFor primary injecting partners:\n\n* Primary injecting partner of an enrolled index participant:\n* 18 years of age or older at enrollment\n* Willing and able to provide informed consent\n* English or Spanish speaking\n* has context menu\n\nExclusion criteria:\n\nFor both index participants and injecting partners:\n\n* Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment\n* Previously participated in this study in any capacity","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.\n\nThe study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted \"booster\" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.\n\nParticipants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.\n\nThis research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.",[25,26,27,28,29,30],"HEPATITIS C (HCV)","Opioid Use Disorder","Substance Use Disorder (SUD)","Drug Use Disorders","Healthcare Access","Harm Reduction",[32,33,34,35,36,37,38,39,40],"People who inject drugs (PWID)","Partner navigation","Dyadic intervention","Post-treatment healthcare engagement","Behavioral intervention","HCV treatment","Injecting partnerships","Feasibility pilot","Substance use","NOT_YET_RECRUITING","2026-06-01",{"date":44,"type":45},"2026-06-08","ACTUAL",{"date":47,"type":19},"2026-09-01",{"date":49,"type":19},"2027-06-30",{"name":51,"class":52},"University of California, San Francisco","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":20,"phases":65,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":53},"100595983","harm-reduction-intervention-for-anabolic-androgenic-steroids-users-a-randomized-controlled-trial-100595983","NCT07039539","Harm Reduction Intervention for Anabolic-androgenic Steroids Users: a Randomized Controlled Trial","SOS-RCT-HR","Inclusion Criteria:\n\n* Anyone over 15 years of age;\n* Planning to use\u002Fincrease the dose of AAS for aesthetic and\u002For physical performance purposes;\n* Plan to use\u002Fincrease the dose of AAS during eight to twelve weeks.\n\nExclusion Criteria:\n\n* Medical prescription for AAS use;\n* Use for sexual reassignment.",true,"15 Years",{"count":64,"type":19},32,[22],"This clinical trial aims to investigate the short and long-term efficacy of a harm reduction intervention in reducing the use of non-clinical anabolic-androgenic steroids (AAS) in abusive users of AAS. As secondary objectives, the study will investigate the intervention's effect on health parameters (i.e., blood), quality of life, sleep quality, body image, eating behavior, depression, anxiety, fatigue, aggressiveness, cardiovascular parameters, muscle strength, body composition and muscle cross-sectional area outcomes.",[68,30,69,70,71],"Drug Abuse","Minimization, Harm","Anabolic Steroids Adverse Events","Brief Intervention",[73,74,75,76,77,78,71],"human enhancement drug","performance and image enhancement drug","anabolic androgenic steroids","drug consumption","doping","harm reduction","2026-05-12",{"date":81,"type":45},"2026-05-18",{"date":83,"type":19},"2026-07-01",{"date":85,"type":19},"2027-12-30",{"name":87,"class":52},"University of Sao Paulo",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":61,"sex":15,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100556587","clinical-decision-support-for-safety-of-opioid-transitions-100556587","NCT06527040","Clinical Decision Support for Safety of Opioid Transitions","Inclusion Criteria: Any primary care encounter where an opioid is prescribed that transitions the patient to a different stage of opioid therapy (acute to subacute after 1 month of opioids; subacute to chronic after 3 months of an opioid)\n\nExclusion Criteria:\n\n* Patients \\\u003C12 and \\>89\n* Patients with active cancer diagnosis in last 1 year\n* Patients with hospice care\u002Fpalliative care order\n* Patients with sickle cell disease diagnosis","12 Years","89 Years",{"count":97,"type":19},200000,"OBSERVATIONAL","The objective of this study is to evaluate the impact of clinical decision support (CDS) alert to notify providers when the opioid prescription being written will result in the patient transitioning into a new phase of opioid therapy. The 2022 CDC clinical practice guideline for prescribing opioids for pain recommends providers reassess patient pain as well as the risks and benefits of opioid therapy before patients transition from acute to subacute treatment (1 month of opioid analgesics) and when patients transition from subacute to chronic opioid treatment (3 months). This study will evaluate a clinical decision support tool identifying patients who will be transitioning between phases as a result of an opioid prescription and suggest a review of patient pain and goals. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will not be notified that the prescription transitions the patient to a new phase but will have access to the same patient pain scales and information. The intervention arm will receive a notification of the transition and suggest review of patient needs and encourage documentation. Opioid transition orders and outcomes of patients will be examined based on medical records data collected during routine care.",[101,30],"Medication Abuse","2026-04-20",{"date":104,"type":45},"2026-04-21",{"date":106,"type":19},"2026-06",{"date":108,"type":19},"2027-06",{"name":110,"class":52},"University of Colorado, Denver",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":61,"sex":15,"minAge":94,"maxAge":95,"enrollmentInfo":117,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100556529","clinical-decision-support-to-increase-use-of-medications-for-opioid-use-disorder-100556529","NCT06526286","Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder","Inclusion Criteria:\n\n* Primary care encounter AND\n* Current opioid prescription (not buprenorphine) and Active opioid medications over the last 90 days OR\n* Documented as on local Pain Registry \"Does the patient fit the criteria to be included on the Pain Registry?\" OR\n* Has active problem list diagnosis of long-term (current) use of opiate analgesic OR\n* Is taking \\>=90 morphine milligram equivalents (MME) per day OR\n* Prior positive toxicology screen for illicit drugs OR\n* Diagnosis of opioid use disorder\n\nExclusion Criteria:\n\n* Active cancer diagnosis in the last 1 year\n* Hospice care\u002Fpalliative care order\n* Sickle cell disease diagnosis",{"count":97,"type":19},"The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will randomize primary care providers at the clinic level to a control arm or intervention arm. The control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. The intervention arm will receive a reminder nudge about the pathway. Buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.",[101,30,26,120],"Supportive Care",{"date":122,"type":45},"2026-04-23",{"date":106,"type":19},{"date":125,"type":19},"2027-05",{"name":110,"class":52},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":61,"sex":15,"minAge":94,"maxAge":95,"enrollmentInfo":133,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":143,"locationsCount":4},"100556590","evaluation-of-clinical-decision-support-in-opioid-tapering-100556590","NCT06527079","Evaluation of Clinical Decision Support in Opioid Tapering","Inclusion Criteria: Primary care patients being tapered from an opioid. Tapering patients:\n\n* Have an active opioid prescription for more than 3 months and\n* Prescribed more than 90 morphine milligram equivalents (MME) per day or\n* Co-prescribed an opioid and benzodiazepine or\n* Received a reduction in opioid dosage by more than 5% MME per day\n\nExclusion Criteria:\n\n* Patients \\\u003C12 and \\>89\n* Patients with active cancer diagnosis in last 1 year\n* Patients with hospice care\u002Fpalliative care order\n* Patients with sickle cell disease diagnosis",{"count":97,"type":19},"The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the risk of withdrawal symptoms, overdose, and to promote tolerance of the tapering. This project will evaluate a clinical decision support (CDS) tool in the form of a clinical care pathway that gives providers information, recommendations, and educational material on strategies for opioid tapering. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will have the clinical care pathway available, but will not be reminded of the pathway when tapering a patient. The intervention arm will receive a nudge when prescribing a tapering opioid strategy to a patient to use the clinical care pathway. The rate of opioid tapering in line with CDC guidelines will be examined as well as long-term patient outcomes of opioid overdose or poisoning using existing patient health records. The study period will be approximately 18 months.",[101,30,26,136,137,138],"Opioid Prescribing","Opioid Overdose","Prevention",{"date":122,"type":45},{"date":141,"type":19},"2026-08",{"date":108,"type":19},{"name":110,"class":52},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":20,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100614044","smoking-harm-reduction-using-e-cigarettes-and-cytisine-100614044","NCT07274475","Smoking Harm Reduction Using E-cigarettes and Cytisine","Exploring Alternative Approaches to Harm Reduction and Cessation for Treatment-Resistant Tobacco Dependence","SHRECC","Inclusion Criteria:\n\n1. Willingness to comply with all study procedures, for the full duration of the study period (12 months);\n2. Age 18 years or older;\n3. Currently smoking 5 or more cigarettes daily; and\n4. Must have regular access to a phone and email to receive study communications and complete study monitoring.\n\nExclusion Criteria:\n\n1. Individuals who smoke only occasionally or have quit smoking prior to the 6-month follow-up;\n2. Daily or almost daily users of e-cigarettes for the past 30 days;\n3. Presence of medical or psychiatric conditions that may interfere with safe participation or compliance with the study protocol, including severe cardiovascular disorders, renal impairment or respiratory conditions;\n4. Known allergy or hypersensitivity to any components of the e-cigarettes, e-liquids, or cytisine;\n5. Pregnant or breastfeeding, or planning to become pregnant within the next 12 months; or\n6. Current use of pharmacological smoking cessation aids or participation in other smoking cessation clinical trials.",{"count":153,"type":19},6000,[22],"Smoking remains the leading cause of preventable death globally, with high prevalence in disadvantaged populations despite access to free nicotine replacement therapy (NRT) and counseling through Ontario's STOP Program. This study aims to evaluate the acceptability, feasibility, and comparative effectiveness of e-cigarettes and cytisine as harm-reduction tools for individuals who continue to smoke despite standard treatments. Over four years, 6,000 STOP participants who smoke ≥5 cigarettes daily at six months post-treatment will be randomized to receive either an e-cigarette starter kit or a 28-day cytisine supply. Data will be collected via REDCap and include biomarkers (NNAL, PAH), self-reported smoking behavior, nicotine dependence, and quality of life. Statistical analyses will assess changes and compare outcomes between groups. Results will inform public health strategies and enhance equitable cessation support for underserved populations.",[157,30,158],"Tobacco Smoking","Nicotine",[160,161,162,163,164,165],"Cytisine","E-cigarettes","Smoking cessation","treatment-resistant","Addiction","Clinical intervention","2026-03-17",{"date":168,"type":45},"2026-03-19",{"date":170,"type":19},"2026-05-01",{"date":172,"type":19},"2028-03",{"name":174,"class":52},"Centre for Addiction and Mental Health",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":61,"sex":15,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":20,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":53},"100544746","noncombustible-nicotine-delivery-systems-as-potential-harm-reduction-tools-for-persistent-cigarette-smokers-100544746","NCT06372899","Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Alternative Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e. speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. 5 or more failed quit attempts and the use of smoking cessation medication on at least one prior attempt.\n4. Have a carbon monoxide (CO) greater than 10 ppm.\n5. Not using any forms of nicotine regularly other than cigarettes\n6. Be willing to switch to e-cigarettes or nicotine pouches for 6 weeks.\n7. Plan to live in the area for the duration of the study.\n8. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form.\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, etc.). Regular e-cigarette and nicotine pouch use is defined as greater than 5 days\u002Fpast 30 days.\n\n   a. Participants agreeing to abstain from using nicotine-containing products other than cigarettes for the duration of the study will be considered eligible.\n2. Current enrollment or plans to enroll in a smoking cessation program over the duration of the study.\n3. Current use of smoking cessation medication\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n4. Breath alcohol reading (BrAC) greater than .000 at Intake.\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, heart disease). Applicable conditions will be evaluated on a case-by-case basis by the Principal Investigator.\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator. Subjects may be deemed ineligible at any point throughout the study.","21 Years",{"count":184,"type":19},200,[22],"This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.",[188,189,30,190],"E-cigarette Use","Cigarette Smoking","Tobacco Use","RECRUITING","2026-03-11",{"date":194,"type":45},"2026-03-12",{"date":196,"type":45},"2024-10-02",{"date":198,"type":19},"2028-03-31",{"name":200,"class":52},"Abramson Cancer Center at Penn Medicine",{"id":202,"slug":4,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":61,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":20,"phases":210,"briefSummary":211,"conditions":212,"keywords":216,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":53},"100593021","NCT07001020","Innovating Technology Solutions for Residents in Support Housing Communities w SUD Through Community-Engaged Research","Innovating Technology Solutions for Residents in Supportive Housing Communities With SUD Through Community-Engaged Research","HousingSUD","Residents:\n\n1. 18 and older;\n2. past or current resident in supportive housing community;\n3. past or current elevated substance use\n\nStaff:\n\n1. 18 or older;\n2. staff at partner agency",{"count":209,"type":19},25,[22],"The goal of this clinical trial is to understand whether a technology-based solution, provided to residents in permanent supportive housing, is acceptable, feasible to implement, and has promise for improving resident stability. The main questions it aims to answer are:\n\n• Is the technology-based, community-defined solution usable, acceptable, feasible, and have promise of effectiveness for improving resident knowledge?\n\nThere is no comparison group, all participants will receive the technology-based intervention. Researchers expect the intervention will include 2 weeks of intervention content that includes videos and incentives for completing content though the solution tested will ultimately be co-defined by our community board.",[213,214,215,30],"Housing Problems","Household Substance Abuse","Substance Use Disorders",[217],"eviction, housing stability, training","2026-03-04",{"date":220,"type":45},"2026-03-06",{"date":222,"type":19},"2026-04-01",{"date":106,"type":19},{"name":225,"class":226},"Oregon Research Behavioral Intervention Strategies, Inc.","INDUSTRY",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":20,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":253},"100580892","teaching-health-resilience-in-a-hospital-setting-a-peer-led-intervention-100580892","NCT06843213","Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention","Teaching Health Promotion and Resilience in Varied Environments: a Peer-led Intervention Following Hospital Discharge","THRIVE","Inclusion Criteria:\n\n* Participants who are: a) admitted to University of Pittsburgh Medical Center (UPMC) Shadyside Hospital, UPMC Presbyterian-Montefiore Hospital, UPMC Mercy Hospital for inpatient or observation status, or b) seen in the Emergency Department setting at UPMC Presbyterian-Montefiore Hospital and UPMC Mercy Hospital.\n* Participants must have a current diagnosis of Opioid Use Disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria.\n* Participants must be at least 18 years of age on day of admission.\n* Participants must be able to speak and read English.\n\nExclusion Criteria:\n\n* Participants diagnosed with dementia and\u002For cognitive impairments.\n* Participants with acute psychiatric complications, such as schizophrenia with acute psychosis, acute mania, or suicidal ideation (which may impact the ability of a participant to consent and actively participate in treatment).\n* Participants who are pregnant or lactating at onset of study.\n* Participants who cannot read or speak English.",{"count":236,"type":19},390,[22],"The purpose of the study is to develop an acceptable, feasible, and effective peer-led bundle of health resilience and promotion services to be delivered in the hospital setting, called the THRIVE intervention.\n\nThe main question it aims to answer is: Will participants receiving the THRIVE intervention have a reduced risk of self-reported non-fatal overdoses OR skin\u002Fsoft tissue infections compared to participants receiving enhanced usual care?\n\nResearchers will compare the THRIVE model to enhanced usual care to see if the THRIVE model helps participants reduce their number of self-reported non-fatal overdoses OR skin\u002Fsoft tissue infections.\n\nIntervention participants will:\n\n* Receive one in-person session from a peer support specialist while in the hospital\n* Receive weekly text messages from the peer support specialist for a 12-week period\n* Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6\n* Complete a baseline, 3-month, and 6-month assessment with Research Assistants\n\nEnhanced usual care participants will:\n\n* Receive a handout with health resilience education and resources in their local area\n* Receive monthly, multiple-choice assessments via text message at Month 1, 2, 3, 4, 5, and 6\n* Complete a baseline, 3-month, and 6-month assessment with Research Assistants",[26,30,240],"Health Promotion",[26,30,242,243],"Peer Support","Peer Support Specialists","2026-02-24",{"date":246,"type":45},"2026-02-27",{"date":248,"type":45},"2025-02-18",{"date":250,"type":19},"2028-08-01",{"name":252,"class":52},"University of Pennsylvania",3,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":15,"minAge":260,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":20,"phases":264,"briefSummary":265,"conditions":266,"keywords":269,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":53},"100524977","a-randomized-clinical-trial-of-a-novel-drug-education-and-diversion-program-idecide-for-middle-and-high-school-students-100524977","NCT06115746","A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students","Inclusion Criteria:\n\n1. Currently enrolled in middle or high school;\n2. Violated school substance use policy within approximately the past month at the time of screening;\n3. Have a parent or legal guardian who is able and willing to provide written informed consent (if under the age of 18);\n4. Competent and willing to provide written informed assent (if under the age of 18) or written informed consent (if age 18 or older);\n5. Able to commit to 9 study visits over approximately one year;\n6. Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator;\n7. Has access to a reliable internet connection and a device that can run Zoom;\n8. Able to read and write comfortably in one of the languages spoken by study staff.\n\nExclusion Criteria:\n\n1. Ever received substance use treatment in an inpatient or specialty care setting;\n2. Ever engaged in intravenous (IV) drug use;\n3. Current daily use of alcohol, non-medical benzodiazepines, and\u002For opioid use.","9 Years","22 Years",{"count":263,"type":19},300,[22],"The primary goal of this study is to test the effectiveness of the iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug education and diversion program, in approximately 300 middle and high school students, who have violated their school substance use policies in the past month, as an alternative to punitive school responses for school-based substance use infractions. This randomized controlled trial will test the hypothesis that adolescents randomized to the iDECIDE curriculum will have improved substance use outcomes (i.e., knowledge, attitudes, and behavior) compared to adolescents in a waitlist control group. The outcomes of this study will measure knowledge of drug effects and brain development, perceptions of harm from substance use, willingness to quit or reduce use, and substance use behavior.",[267,30,268],"Substance Use","Adolescent Behavior",[270,271,272,273,274,275,164,276,277],"Adolescent","Diversion program","iDECIDE","Tier 2","School","Substance use prevention","Early intervention","Targeted prevention","2025-10-28",{"date":280,"type":45},"2025-10-30",{"date":282,"type":45},"2023-11-17",{"date":284,"type":19},"2028-07-31",{"name":286,"class":52},"Massachusetts General Hospital",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":53},"100606017","shelter-harm-reduction-evaluation-100606017","NCT07170072","Shelter HArm Reduction Evaluation","Community-based Evaluation of a Novel, System-wide Harm Reduction Strategic Plan for People Experiencing Homelessness in New York City","SHARE","Inclusion Criteria:\n\nFor Aims 1a, 1b, and 2: There will be no participant enrollment or direct contact with individuals as these aims will involve the use of an analytic dataset comprised of linked administrative NYC homeless services, Medicaid, and vital records. The dataset will include records for individuals who entered the NYC DHS single-adult shelter system during calendar years 2021-2026, as well as a matched comparison group(s) (as identified through Medicaid data) during the same years. The matched comparison group will be comprised of individuals age 18 and older with active Medicaid coverage at the time of observation.\n\nFor Aim 3 Homeless Services Client participant group: To be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* Adult 18 year of age or older\n* Speak English\n* Is staying or has stayed in an NYC single-adult shelter that has implemented HRSP interventions\n* Report past-year drug use\n* Able and willing to provide consent\n\nFor Aim 3 Homeless Services Staff participant group: To be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Speak English\n* Works at an adult shelter service provider agency that implemented HRSP or received HRSP interventions (role may include case manager, security staff, shelter director, medical staff, organizational leadership)\n* Able and willing to provide consent\n\nFor Aim 3 Homeless Services Stakeholder participant group: To be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Speak English\n* Works in a role in which they have key insight to the HRSP interventions, including planning and implementation (role may include homeless services administrator or other key stakeholder)\n* Able and willing to provide consent\n\nExclusion Criteria:\n\nAims 1a, 1b, and 2: Children under age 18 years of age will be excluded.\n\nAim 3: Under age 18 years old, currently a prisoner (we are not sampling from locations where we expect to encounter prisoners), unable to communicate in English (because the interview and focus group guides will not be validated for use in other languages), and unable to provide informed consent.\n\nFor Aim 3 Homeless Services Client participant group: those who are not staying or have not stayed at a shelter with HRSP interventions and those who do not report past-year drug use will not be excluded.\n\nFor Aim 3 Homeless Services Staff participant group: those who have not been employed in a shelter with the HRSP interventions will be excluded. In alignment with standard techniques of purposeful sampling and the study goal of ensuring a range of experiences is captured in the qualitative interviews, additional targeting or exclusion criteria might be set by investigators as needed to ensure that a diverse range of experiences is included among qualitative interview participants.",{"count":296,"type":19},80,"The proposed study will use mixed methods research to examine overdose and other health-related impacts of harm reduction initiatives in NYC homeless shelters.",[299,30],"Overdose","2025-09-05",{"date":302,"type":45},"2025-09-12",{"date":304,"type":45},"2025-07-01",{"date":306,"type":19},"2026-09-30",{"name":308,"class":52},"NYU Langone Health",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":15,"minAge":182,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":20,"phases":319,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":53},"100570035","phase-3-electronic-harm-reduction-treatment-for-alcohol-100570035","NCT06702007","Electronic Harm Reduction Treatment for Alcohol","eHaRT-A: Adapting an Evidence-based, In-person Harm Reduction Treatment Into a Virtual Care Telehealth Intervention for People With Lived Experience of Homelessness and Alcohol Use Disorder","eHaRT-A","Inclusion Criteria:\n\n* Being at least 21 years of age\n* Speak English fluently\n* Currently a registered client at one of the Housing First sites\n* Currently drinking (has used alcohol in the past 2 weeks)\n* Meeting criteria for \"current\" (e.g., past-year) AUD according to the Diagnostic and Statistical Manual of Mental Health Disorders, Fifth Edition (determined as scoring \\>= 2 on the SCID-5-CV)\n\nExclusion Criteria:\n\n* Enrollment in any related treatment studies (including studies by this research team)\n* Refusal or inability to consent\n* Constituting a risk to the safety and security of residents or staff",{"count":318,"type":19},160,[320],"PHASE3","The goal of this project is to transform a successful, face-to-face harm-reduction treatment (HaRT-A) into a digital format, creating eHaRT-A. This new platform is specifically designed for people who have experienced homelessness and an alcohol use disorder (AUD), living within the framework of permanent, supportive, Housing First (HF) facilities. We hypothesize eHaRT-A will be more effective than the standard HF services in reducing alcohol-related harm and improving the overall quality of life for participants.",[323,30,324],"Alcohol Use Disorder","Housing First (eg. Permanent Supportive Housing)",[326,327,328,329],"Telehealth","Alcohol-Related Harm","Community Based Participatory Research","Lived experience of chronic homelessness","2025-07-02",{"date":332,"type":45},"2025-07-08",{"date":334,"type":45},"2025-01-20",{"date":336,"type":19},"2027-08-31",{"name":338,"class":52},"University of Washington",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":61,"sex":15,"minAge":346,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":20,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":53},"100478906","our-healthbox---evaluating-interactive-dispensing-systems-for-low-barrier-access-to-hiv-testing-and-harm-reduction-100478906","NCT05516069","Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.","Reaching HIV Undiagnosed: Implementation and Evaluation of Interactive Dispensing Systems for Low-barrier Access to Rapid Testing and Harm Reduction Supplies With Linkage to Care for Marginalized and Hard-to-reach Populations in Canada.","Inclusion Criteria:\n\n* Age 16 years or older (except for Quebec: age 18 years or older)\n* Person living in Canada (Canadian resident)\n* Able to provide consent in English or French (via the machine screen)\n\nExclusion Criteria:\n\n* Does not meet all inclusion criteria","16 Years",{"count":348,"type":19},5000,[22],"When REACH Nexus at MAP Centre for Urban Solutions out of St. Michael's Hospital launched its signature program, I'm Ready in 2021, our goal was to democratize access to free HIV self-testing to reach the undiagnosed in Canada. The program, the first of its kind in Canada has been successfully rolling out 50,000 free, HIV self-tests and connecting participants via a mobile app on an iOS or Android smart phone to care.\n\nWhile this is an important milestone in improving access, REACH knows that more needs to be done. An estimated 20-30% of undiagnosed individuals do not have access to a phone to order the HIV self-tests, and many face multiple barriers to accessing healthcare and harm reduction support: chaotic life circumstances, addiction challenges, stigma and more.\n\nEveryone in Canada should have equitable access to the health care they need. But REACH knows that this is not the case.So, REACH is working hard to change this. hese ongoing barriers inspired us to continue creating innovative solutions, and launch our second signature program, Our Healthbox. Our Healthbox meets people where they are, with what they need for their health and well-being. This program is scaling up innovations in health technologies to reach undiagnosed individuals with HIV. These smart interactive vending machines will be strategically located across Canada. The goal is to reach people where they live to provide free and low barrier access to HIV self-testing kits, STBBI testing and other harm reduction supplies.\n\nParticipation in Our Healthbox, as with I'm Ready, also gives us the opportunity to collect important data that will continue to inform and guide REACH Nexus' work to grow and scale innovative health solutions across the country.",[352,353,30,354,355],"HIV","HIV Self-testing","Sexually Transmitted Diseases","Blood-Borne Infections","2024-07-17",{"date":358,"type":45},"2024-07-19",{"date":360,"type":45},"2023-01-23",{"date":362,"type":19},"2026-06-30",{"name":364,"class":52},"Unity Health Toronto"]